Very interestingly, a human anti-IL-17A monoclonal antibody to treat Crohn's disease showed that blockade of IL-17A in humans was ineffective and higher rates of adverse events were noted compared with the placebo group (Hueber et al., 2012). The gene discussed is IL17A; the disease is Crohn disease.